Allezoe Medical Holdings, Inc.
OTC Bulletin Board : ALZM

May 09, 2011 09:01 ET

Allezoe Medical Holdings (ALZM) Announces Organ Transport Systems, Inc.'s (OTS) Research Collaboration Expanding to Duke University Medical Center

OTS's new research on discarded heart donations examines the potential to resuscitate organs with LifeCradle® technology

FRISCO, TEXAS--(Marketwire - May 9, 2011) -Allezoe Medical Holdings, Inc. (OTCBB:ALZM) today announced that Organ Transport Systems, Inc. its wholly-owned subsidiary, has expanded research on its LifeCradle® HR device for donor heart preservation to include a new collaboration with Duke University Medical Center ("Duke").

OTS is working with researchers at Duke University Medical Center in Durham, NC, on a recently-initiated, pre-clinical research project with the cardiac transplant team under the direction of Dr. Carmelo A. Milano. OTS will be providing the LifeCradle® device to the research team for them to evaluate the potential resuscitation of human donor hearts that are currently being discarded.

Current heart transplantation guidelines require that donor hearts for transplantation only be procured from "brain dead", heart beating donors, which has significantly limited the supply of transplantable hearts. At the same time, the waiting list for donor hearts in the U.S. continues to expand due to heart disease and other factors. In addition to researching discarded human hearts, the Duke researchers are conducting a series of swine experiments. In the recently-initiated study, the Duke team is examining the results when the donor swine heart is stopped for a period of time, then perfused in the OTS LifeCradle® for a couple hours, and then finally transplanted in a recipient swine for validation of cardiac function.

The principal investigators, Drs. Valentino Piacentino, III and Milano, have been awarded grant funding from the Duke Translational Research Institute to support the project. Dr. Milano states, "If we can successfully demonstrate resuscitation of these currently discarded donor hearts using the OTS LifeCradle®, it would make a major impact in cardiac transplantation."

Dr. Thomas D. Franklin, Jr., PhD, Exec. VP of Research & Regulatory Affairs at OTS, adds, "We are very excited about working with the Duke research team to potentially expand the use of the OTS LifeCradle® beyond the preservation of just acceptable donor hearts. If discarded hearts can be usable, providing additional hearts for transplantation, this research has the potential to add a completely new dimension to the solutions we are working on to offer the medical community and its growing waitlist of patients in desperate need of a heart transplant."

The Duke research project is entitled Resuscitation & evaluation of human delayed cardiac death (DCD) donor hearts on an ex vivo perfusion apparatus.


This announcement is not an offer to sell any Allezoe ("ALZM") related securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of ALZM may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and includes, without limitation, statements regarding ALZM's plan of business operations, product research and development activities, anticipated revenues and expenses and potential contractual arrangements and obligations. Also, our management may make forward-looking statements orally to investors, analysts, the media and others. Any statements made in this news release about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. These risks and others are included from time to time in documents we file with the Securities and Exchange Commission, including but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks. Other unknown or unpredictable factors also could have material adverse effects on our future results. Accordingly, you should not place undue reliance on these forward-looking statements. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The Company takes no obligation to update or correct its own forward-looking statements, except as required by law or those prepared by third parties that are not paid by the Company. The Company's SEC filings are available at

Contact Information